Jorda Radek
O mně
See my attached CV.
Journals
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022). Expert Opinion on Therapeutic Patents. 2023, 33(2), 67-87, ISSN: 1354-3776, PMID: 36975020,
Anticancer effect of zanubrutinib in HER2-positive breast cancer cell lines. Investigational New Drugs. 2023, 41(2), 210-219, ISSN: 0167-6997, PMID: 36913160,